# A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

> **NCT02945020** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 15 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran etexilate mesylate
- **DRUG:** Odalasvir (ODV)
- **DRUG:** Simeprevir (SMV)

## Key facts

- **NCT ID:** NCT02945020
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-10
- **Primary completion:** 2017-01-09
- **Final completion:** 2017-01-20
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945020, "A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02945020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*